We caught up with Rohit Aggarwal to discuss the efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis (Clinical Trial Identifier: NCT02728752). The abstract ‘Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)’ (ABSTRACT NUMBER: 0955) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you tell us a little about dermatomyositis and the unmet needs in its treatment? (0:24)
- What is the role of IV immune globulin (IVIG) in the treatment of dermatomyositis? (1:28)
- What were the aims and design of the ProDERM study? (2:39)
- What were the findings of the study in terms of efficacy, safety and tolerability? (3:50)
- What will be the impact of these findings on clinical practice? (6:27)
Disclosures: Dr. Aggarwal has received consulting fees from various pharmaceutical companies including Octapharma, BMS, Mallinckrodt, Pfizer, Janssen, Abbvie, EMD serono, AstraZeneca, Csl Behring, Kezar, Kyverna, Agrenx, Alexion, Q32, Corbus, BI.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Dermatological Conditions
Esther van Zuuren, EADV 2021: Topical Therapies in Rosacea
It was a pleasure to speak with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) about current and emerging topical therapies in rosacea. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you give us an overview of the current […]
Esther van Zuuren, EADV 2021: Rosacea Classification
It was a pleasure to be able to catch up with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) to discuss rosacea classification and how this can impact treatment choices. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you […]
Dedee Murrell, AAD VMX 2021: BELIEVE Phase 2 Study of Rilzabrutinib in Pemphigus
It was a pleasure to be able to speak with Prof. Dedee Murrell (St George Hospital, University of New South Wales, Sydney, Australia) about the BELIEVE Phase 2 (Part A) Study (NCT02704429) which investigated the oral BTK inhibitor, rilzabrutinib, in pemphigus. Her abstract entitled ‘Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!